52
Participants
Start Date
March 19, 2021
Primary Completion Date
September 9, 2022
Study Completion Date
September 9, 2022
Odevixibat
Odevixibat is a small molecule and selective inhibitor of IBAT.
Placebo
Placebo identical in appearance to experimental drug (odevixibat).
Starship Child Health, Auckland
Cliniques Universitaires Saint-Luc Bruxelles, Brussels
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center, New York
The Childrens Hospital at Montefiore Albert Einstein School of Medicine, The Bronx
Charité-Universitätsmedizin Berlin, Berlin
APHM, Marseille
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Johns Hopkins Hospital, Baltimore
ASST Papa Giovanni XXIII, Bergamo
Medizinische Hochschule Hannover, Hanover
Istanbul University Medical Faculty Hospital, Fatih
Azienda Ospedale Università Padova, Padua
AOU Meyer, Florence
Antenne pédiatrique du CIC - Hopital Jeanne De Flandre, Lille
University of Malaya Medical Centre, Kuala Lumpur
Children's Mercy Hospital and Clinics, Kansas City
Hôpital Femme Mère Enfant de Lyon, Bron
Universitätsklinik für Kinder-und Jugendmedizin Tübingen, Tübingen
Hopital Necker Enfants Malades, Paris
University of California - San Francisco, San Francisco
Oregon Health Science University School of Medicine, Portland
Schneider Children's Medical Center of Israel, Petah Tikva
Sharie Zedek, Jerusalem
Boston Children's Hospital, Boston
CHU Sainte-Justine, Montreal
Bambino Gesù Children's Hospital, Rome
Universitair Medisch Centrum Groningen (UMCG), Groningen
University Medical Centre Utrecht, WKZ, Utrecht
Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw
Hacettepe Üniversitesi İhsan Doğramacı Çocuk Hastanesi, Ankara
King's College Hospital, London
Lead Sponsor
Albireo
INDUSTRY